Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 31 of 272 for:    Betamethasone

Pharmacokinetics (PK) and Modeling of Betamethasone Therapy in Threatened Preterm Birth

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02793700
Recruitment Status : Recruiting
First Posted : June 8, 2016
Last Update Posted : June 19, 2019
Sponsor:
Information provided by (Responsible Party):
David Haas, Indiana University

Brief Summary:
Respiratory distress syndrome (RDS) is a life-threatening condition for premature neonates. Antenatal glucocorticoids have been used clinically in women with threatened preterm birth to accelerate lung maturation for more than 40 years. The current treatment strategy for women with threatened preterm delivery is for a standard, "one size fits all" dosing with either betamethasone (BMZ) or dexamethasone. It is well known that pregnancy introduces additional variability in response to medication therapy with different physiological changes and alterations in the activity of drug metabolizing enzymes. The objective of this project is to evaluate the pharmacokinetic (PK), pharmacodynamic, and pharmacogenetic parameters of betamethasone (BMZ) and determine the differences in response and benefit in pregnancy. An individualized dosing approach to medications in pregnancy, such as BMZ, is crucial to optimize efficacy of this important medication.

Condition or disease
Premature Labor

Detailed Description:
After consent, a maternal sample of whole blood will be obtained for DNA isolation. Investigators will collect plasma samples at 4 time points on all participants. These will be done at baseline (pre-dose), and 0.5-2 hours, 4-6 hours, and 22-24 hours after the first dose of BMZ is administered. Investigators will obtain serum for estriol measurement on all participants before or within 2 hours of antenatal corticosteroid administration and about 24 hours after each dose is given (betamethasone is administered as 2 doses 24 hours apart). Investigators will obtain a saliva sample for measurement of estriol at the same times. Participants will be offered optional participation in a more detailed PK portion of the study. Participants who consent to this part of the study will have additional plasma samples obtained at a schedule of sampling of approximately 10-15 hours after the first dose and then 6-8 hours, 24, and 48 hours after the 2nd dose. One sample will be collected at each of these times. At the time of delivery, umbilical cord blood will be collected before being discarded for DNA, serum and plasma. Four placenta sections will be collected. A maternal blood sample will also be obtained for serum and plasma. If the investigators are unable to obtain umbilical cord blood, a buccal swab will be collected from the baby for DNA extraction. A chart review will be done on the infant within 30 days of birth to review and record neonatal outcomes.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Pharmacokinetics and Modeling of Betamethasone Therapy in Threatened Preterm Birth
Study Start Date : July 2016
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2021





Primary Outcome Measures :
  1. Diagnosis of respiratory distress syndrome [ Time Frame: up to 30 days of life ]
    The diagnosis of RDS made by the neonatologist staff based on clinical criteria


Biospecimen Retention:   Samples With DNA
Maternal whole blood Cord blood Placenta


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Women 18 years of age or older who are between 23-34 weeks gestation and being administered BMZ for fetal lung maturity.
Criteria

Inclusion Criteria:

  • Gestational age between 23-34 weeks with a diagnosis of threatened preterm labor or preterm premature rupture of membranes, or other diagnosis with a high likelihood of preterm delivery where the provider is recommending administering antenatal corticosteroids
  • Singleton gestation
  • Live fetus at the time of enrollment
  • Being administered antenatal corticosteroids to enhance lung maturity
  • Ability to provide written informed consent to participate in the study

Exclusion Criteria:

  • Maternal age <18 years old
  • Major congenital anomalies
  • Known severe abruptio placentae at the time of enrollment
  • Multiple gestations
  • Hepatic failure (history of hepatic failure, cirrhosis or 2- fold increase in Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT)
  • Renal failure (serum creatinine > 2 mg/dl)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02793700


Contacts
Layout table for location contacts
Contact: David M Haas, MD, MS 317-880-3949 dahaas@iu.edu

Locations
Layout table for location information
United States, Indiana
Eskenazi Hospital Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Hayley Trussell, RN    317-880-3960    hktrusse@iupui.edu   
IUH Methodist Hospital Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Hayley Trussell, RN    317-880-3960    hktrusse@iupui.edu   
Sponsors and Collaborators
Indiana University
Investigators
Layout table for investigator information
Principal Investigator: David M Haas, MD, MS Indiana University

Layout table for additonal information
Responsible Party: David Haas, Dr, MD, MS, Indiana University
ClinicalTrials.gov Identifier: NCT02793700     History of Changes
Other Study ID Numbers: 1604640151
First Posted: June 8, 2016    Key Record Dates
Last Update Posted: June 19, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: No plan for availability of individual participant data
Keywords provided by David Haas, Indiana University:
Betamethasone
Additional relevant MeSH terms:
Layout table for MeSH terms
Betamethasone
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Betamethasone benzoate
Betamethasone sodium phosphate
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents